CGIM
AKBA icon

Cannon Global Investment Management’s Akebia Therapeutics AKBA Stock Holding History

Cannon Global Investment Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-28,000
Closed -$51.2K – 37
2024
Q1 		$51.2K Buy
+28,000
New +$44.8K 0.14% 60

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Cannon Global Investment Management's AKBA Position: Q2 2024 in Review

Cannon Global Investment Management sold out of Akebia Therapeutics (AKBA) in Q2 2024, closing a stake of 28,000 shares — an estimated $51.2K sold.

Cannon Global Investment Management first reported a position in AKBA in Q1 2024 and held it in 1 quarter. The position peaked at $51.2K in Q1 2024. 103 funds tracked by Wall St. Rank hold AKBA as of Q2 2024.

  • Cannon Global Investment Management reported no remaining Akebia Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Cannon Global Investment Management sold 28,000 Akebia Therapeutics shares in Q2 2024, an estimated $51.2K.
  • Cannon Global Investment Management first reported a position in Akebia Therapeutics in Q1 2024 and held it in 1 quarter.
  • Cannon Global Investment Management's Akebia Therapeutics position peaked at $51.2K in Q1 2024.
  • 103 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2024.

Based on Cannon Global Investment Management's 13F filing for Q2 2024, filed 2 Aug 2024.